Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Asok Antony · RLR VA MEDICAL CENTER · 2023 — Despite the advent of effective anti-Human Papillomavirus (HPV) vaccines, there are no biological agents to reliably prevent ~80 million Americans from transmitting their infectious HPV viral particles to sexual partners. Earlier we determined that the post-translational homocysteinylation of an mR…
Norbert Pardi · UNIVERSITY OF PENNSYLVANIA · 2023 · $613,686 — ABSTRACT Influenza virus is one of the most important human infectious diseases. The influenza mortality is estimated to be approximately 650,000 per year worldwide, in addition, occasional global pandemics can infect up to 20- 40% of the world's population. Licensed influenza virus vaccines require…
Hamideh Parhiz · FRED HUTCHINSON CANCER CENTER · 2023 · $893,464 — PROJECT SUMMARY/ABSTRACT Modification of autologous T cells with chimeric antigen receptor (CAR) molecules was first proposed nearly 30 years ago as a therapy for people living with HIV. Since then, CAR-T cells have emerged as a potent and highly successful therapy for liquid tumors, while HIV-speci…
BRUNO DE BEZERRIL ANDRADE · VANDERBILT UNIVERSITY MEDICAL CENTER · 2023 · $750,333 — PROJECT SUMMARY Recent studies from our group have reported a peripheral blood correlate of risk (COR) transcriptional signature that identified individuals with incipient (asymptomatic) TB who progressed to active (symptomatic) TB disease within 12 months. We have also identified human genetic poly…
Aaron M. Johnson · UNIVERSITY OF COLORADO DENVER · 2023 · $181,741 — PROJECT SUMMARY Specific long noncoding RNAs (LncRNAs) that are overexpressed in breast cancer aid in diagnosis and promote molecular mechanisms that drive breast cancer progression. Our recent work has identified a breast- cancer associated LncRNA that converts from an oncogene to a tumor suppress…
Paul Bates · UNIVERSITY OF PENNSYLVANIA · 2023 · $581,039 — Severe Fever with Thrombocytopenia Syndrome virus (SFTSV) is a pathogenic, tick-transmitted bunyavirus that can cause a severe febrile hemorrhagic-like disease with case fatality rates of up to 30%. Discovered during a 2009 outbreak of febrile illness in China, the geographic distribution of SFTSV e…
Jinjun Shi · BRIGHAM AND WOMEN'S HOSPITAL · 2023 · $542,677 — ABSTRACT Recent clinical success of mRNA vaccines for COVID-19 has sparked enormous interest in mRNA therapy for a wide range of biomedical applications including protein replacement therapy. However, one unique challenge associated with mRNA therapy is dealing with the transient efficacy due to its…
Xiaorong Lin · UNIVERSITY OF GEORGIA · 2023 · $188,750 — Abstract Cryptococcal meningoencephalitis is responsible for 15% of the total deaths of AIDS patients. There is no vaccine available for cryptococcosis and the disease claims hundreds of thousands of lives each year, with the global mortality rates of ~70% despite current antifungal therapies. The …
HONGMIN LI · UNIVERSITY OF ARIZONA · 2023 · $767,382 — Abstract: Flaviviruses are primarily insect-borne, associated with global morbidity and mortality, and found on every inhabited continent. Unfortunately, current therapeutic options for treating diseases associated with these viruses are limited. All flaviviruses encode methyltransferases (MTases)—f…
Jie Sun · UNIVERSITY OF VIRGINIA · 2023 · $707,188 — PROJECT SUMMARY/ABSTRACT In the wake of a global pandemic caused by the ancestral strain of SARS-CoV-2, infections with emerging variant strains are an ongoing cause of morbidity and mortality. Robust respiratory mucosal immune responses to SARS-CoV-2 infection and/or vaccination are vital to preven…
Tian Wang · UNIVERSITY OF TEXAS MED BR GALVESTON · 2023 · $613,059 — SUMMARY: The Coronavirus disease 2019 virus (COVID-19) pandemic has made a devastating impact on global public health and economy over the past three years. Despite the success in rapid progress of COVID-19 vaccine development, increasing rates of variants of concern (VOCs) with enhanced viral trans…
CARL H. JUNE · UNIVERSITY OF PENNSYLVANIA · 2023 · $2,782,255 — OVERALL PROJECT SUMMARY / ABSTRACT The long-term goals of this renewal P01 are to develop next generation immunotherapy with chimeric antigen receptor (CAR) T cells and to translate this research into new therapies with curative potential for patients with blood cancer. The CAR developed at our cent…
Owen S Fenton · UNIV OF NORTH CAROLINA CHAPEL HILL · 2023 · $226,495 — ABSTRACT Melanoma is the deadliest form of skin cancer. The FDA-approved immune checkpoint inhibitors targeting PD1 and CTLA4 and the targeted therapies against BRAF and MEK have greatly improved overall survival in metastatic melanoma. Nevertheless, many patients die from metastatic melanoma inclu…
Benedict Smail · DANA-FARBER CANCER INST · 2023 · $22,942 — Project Summary The objective of this research proposal is to characterize the enzymatic activities of the reverse transcriptase (RT) of the human long interspersed element 1 (LINE-1, L1 RT). LINE-1 sequences constitute 17% of the human genome, and L1 RT activity is responsible for approximately 40%…
David M Koelle · UNIVERSITY OF WASHINGTON · 2023 · $558,723 — Project Summary: The waning of immunity has a major impact on morbidity and mortality in the aged. Antigen-specific, acquired, and especially T-cellular is important in host defense against chronic intracellular pathogens and cancer. Infections with these microbes and skin cancers with high mutation…
Stephanie Lina Gaw · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2023 · $683,909 — ABSTRACT Passive transfer of immunoglobulins (IgG) against SARS-CoV-2 occurs from the mother to fetus by transplacental transfer and may protect the neonate against infection or cause disease. Recent studies have shown maternal SARS-CoV-2 infection leads to the dysregulation of infant immune respons…
Justin Richner · UNIVERSITY OF ILLINOIS AT CHICAGO · 2023 · $614,090 — Nearly 400 million people are infected with dengue virus (DENV) each year through the bite of infected mosquitos concentrated in the tropical and subtropical regions of the world. Symptoms can range from febrile illness to severe dengue that manifests as plasma leakage, sudden loss of blood pressure…
SANDHYA VASAN · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · 2023 · $619,289 — Project Summary/Abstract An HIV-1 (HIV) vaccine capable of eliciting broad and potent neutralizing antibody (Ab) response to HIV envelope (Env) remains elusive. HIV has a high mutation rate, Env is highly glycosylated as well as conformationally dynamic and, well-characterized broadly neutralizing r…
TINEKE CANTAERT · INSTITUT PASTEUR DU CAMBODGE · 2023 · $582,693 — We currently have a very limited understanding of the factors, either genetic or immune-related, conferring protection to clinical Plasmodium vivax (Pv) malaria. Deciphering the mechanisms underlying such protection would allow the design of tailored intervention strategies for the elimination of Pv…
Elias Sayour · UNIVERSITY OF FLORIDA · 2023 · $434,992 — Project Summary While activated T cells cross the blood-brain barrier (BBB), immunotherapy has yet to be harnessed for targeted therapy due to GBM’s heterogeneity and immunosuppressive microenvironment. Unleashing immunotherapy against GBM requires new technologies that activate the tumor microenvir…